An observational study on targeted therapy for patients with unresectable or metastatic BRAF V600E mutant Melanoma: TAVIE-Skin.
An observational study on targeted therapy for patients with unresectable or metastatic BRAF V600E mutant Melanoma: TAVIE-Skin.
A prospective non interventional study on targeted therapy for patients with unresectable or metastatic BRAFV600E mutant melanoma (TAVIE-Skin)
Brief summary
In current clinical practice, patients with a BRAF-mutant unresectable or metastatic melanoma may be treated with a combination of BRAF and MEK inhibitors (BRAFi/MEKi). Pierre Fabre has developed TAVIE-Skin, a digital application (app), to support these patients in their daily life.
The aim of TAVIE-Skin app is (i) to deliver the necessary information and education support to the patient (for example information on the pathology, on treatments, symptoms and side effects) (ii) to keep track of the medications taken throughout the days (iii) to assist patients in identifying side effects.
The main purpose of this study is to characterize patients with BRAF-mutant unresectable or metastatic melanoma patients in Europe using TAVIE-Skin app.
Contact Us
Need more information, click on the button to have access to the contact form.
Access to Lay Protocol Synopsis
Un résumé du protocole rédigé en termes simples et décrivant les objectifs de l’étude vous est proposé